Want to see IN:ONESOURCE full AI Analyst Report?
Top Page
OneSource Specialty Pharma Limited
(ONESOURCE)
Select Model
Select Model
Rating:43Neutral
Price Target:
₹1,497.00
▼(-9.46% Downside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by weak financial performance: strong revenue growth is currently accompanied by materially worse profitability and substantial ongoing cash burn. Technicals add further pressure with the stock trading below major moving averages and negative momentum indicators. Valuation is also constrained by losses (negative P/E) and the absence of a stated dividend yield.
Positive Factors
Strong Revenue Expansion
The sharp FY2026 top-line acceleration indicates meaningful growth in demand or business activity. Sustaining this expansion could improve operating scale over the next several quarters, although profitability must recover for growth to create durable value.
Negative Factors
Severe Profitability Deterioration
The shift into a large loss shows that recent revenue growth is not translating into earnings. Sustained margin pressure or elevated costs could weaken reinvestment capacity and delay the path to self-funded expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Expansion
The sharp FY2026 top-line acceleration indicates meaningful growth in demand or business activity. Sustaining this expansion could improve operating scale over the next several quarters, although profitability must recover for growth to create durable value.
Read all positive factors
OneSource Specialty Pharma Limited (ONESOURCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹175.79B
Dividend YieldN/A
Average Volume (3M)3.94K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth27.15%
EPS Growth40.45%
CountryIN
Employees1,412
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,669,990
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.13
Revenue Forecast (FY)₹22.53B
OneSource Specialty Pharma Limited Business Overview & Revenue Model
Company Description
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts it...
How the Company Makes Money
null...
OneSource Specialty Pharma Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
68
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 8.02B | 14.22B | 14.45B |
| Gross Profit | 4.58B | 4.56B | 10.10B |
| EBITDA | 2.92B | 3.04B | 3.61B |
| Net Income | 1.09B | -738.03M | -2.10M |
Balance Sheet | |||
| Total Assets | 80.13B | 82.10B | 75.50B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.03B | 36.21M |
| Total Debt | 12.95B | 15.04B | 9.42B |
| Total Liabilities | 21.09B | 23.79B | 209.75M |
| Stockholders Equity | 59.04B | 58.31B | 58.81B |
Cash Flow | |||
| Free Cash Flow | -3.69B | -6.80B | -1.96B |
| Operating Cash Flow | -399.21M | -1.11B | -24.69M |
| Investing Cash Flow | -2.51B | -4.95B | -25.05M |
| Financing Cash Flow | 2.31B | 4.79B | 66.47M |
OneSource Specialty Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹161.23B | 58.67 | ― | 0.61% | -6.72% | -22.67% | |
73 Outperform | ₹111.52B | 43.45 | ― | 0.22% | -27.51% | -34.49% | |
56 Neutral | ₹27.15B | 39.83 | ― | ― | -20.86% | -34.46% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹160.82B | 72.46 | ― | 0.31% | -3.41% | -56.45% | |
49 Neutral | ₹667.53B | 120.41 | ― | 0.12% | 9.83% | 5.07% | |
43 Neutral | ₹175.79B | -361.27 | ― | ― | 27.15% | 40.45% |
* General Sector Average
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,512.25
-343.15
-18.49%
IN:BIOCON
Biocon Limited
414.60
56.43
15.75%
IN:BLUEJET
Blue Jet Healthcare Limited
588.30
-97.44
-14.21%
IN:CONCORDBIO
Concord Biotech Ltd.
1,549.00
-135.13
-8.02%
IN:DCAL
Dishman Carbogen Amcis Ltd.
172.05
-97.15
-36.09%
IN:SYNGENE
Syngene International Ltd.
406.55
-240.27
-37.15%
OneSource Specialty Pharma Limited Corporate Events
OneSource Specialty Pharma Publishes Unaudited Q1 FY27 Results in Newspapers
Jul 26, 2026
OneSource Specialty Pharma Limited has notified the stock exchanges that it has published newspaper advertisements containing extracts of its unaudited financial results for the quarter ended June 30, 2026. The disclosures, carried in the Financia...
OneSource Specialty Pharma Grants ESOP Shares, Marginally Ups Equity Capital
Jul 24, 2026
OneSource Specialty Pharma Limited has approved the allotment of 2,900 equity shares under its Employee Stock Option Plan 2021 to eligible staff following the exercise of vested options. The new shares, issued at an exercise price of INR 278 per s...
OneSource Specialty Pharma Delivers Strong Q1 FY27 Results, Reaffirms FY28 Guidance
Jul 24, 2026
OneSource Specialty Pharma reported strong Q1 FY27 results, with revenue rising 37% year-on-year to ₹4,490 million and EBITDA climbing 39% to ₹1,233 million, expanding margins to 27.5%. The growth was driven by commercial launches of s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.